News

Myasthenia gravis (MG) patients in Norway who were treated with intravenous immunoglobulin (IVIG) had 2.3 times higher direct medical costs during the first year after a diagnosis than those who didn’t receive IVIG treatment. That’s according to a study that also found that people with MG treated…

Patients should be monitored for symptoms of myasthenia gravis (MG) for approximately six months after starting treatment with statins, common blood cholesterol-lowering medications, according to a study. Hong Kong-based researchers found a significantly increased risk for MG onset and exacerbation, or worsening, in the first seven months after…

Short-term use of cyclophosphamide — given in six monthly cycles, followed by maintenance immunotherapy — markedly reduced the clinical severity of hard-to-treat myasthenia gravis (MG), according to a study by researchers in Australia and the U.K. The therapeutic response seen among patients also allowed a reduction in the…

A 70-year-old man was diagnosed with myasthenia gravis (MG) and with a mass in his thymus, a small, immune cell-producing gland in the upper chest, that is not usually found in elderly adults with MG, a case study from India reports. The man began exhibiting disease symptoms, including…

An investigator-initiated clinical trial will assess the safety and efficacy of NKX019, Nkarta’s investigational natural killer (NK) cell therapy for autoimmune diseases, in people with myasthenia gravis (MG). The open-label Phase 1 trial will be led by researchers at the University of California, Irvine, and the University…

People with myasthenia gravis (MG) who experience exacerbations tend to require longer and more frequent hospital stays, according to a recent study. Findings from the study, which analyzed data from a U.S. Veterans Affairs (VA) healthcare database, also suggest the risk of exacerbations is higher in people with MG…

The investigational cell therapy Descartes-08 led to durable reductions in disease severity for people with myasthenia gravis (MG), according to updated Phase 2b trial results presented by Cartesian Therapeutics, its developer. “Data reported today add to the growing body of evidence supporting the potential for Descartes-08 to provide…

The presence of antibodies targeting titin, a type of muscle protein, in patients with myasthenia gravis (MG) not associated with a thymus tumor is related to more frequent hospitalizations, according to a study in China. Frequent hospitalizations hurt quality of life and mental health for people with MG, and…

A man with a 16-year history of hard-to-treat generalized myasthenia gravis finally saw his disease successfully managed with Soliris (eculizumab) and then with Ultomiris (ravulizumab) — highlighting the efficacy of these newer treatments for myasthenia gravis (MG) — according to a new case study. Indeed, its author called…

Treatment with Vyvgart (efgartigimod) may rapidly and safely ease symptoms during an impending myasthenic crisis in people with myasthenia gravis (MG), according to a study in China. Impending myasthenic crisis, or IMC, refers to symptoms rapidly worsening within a short time that may lead to a myasthenic crisis,…